(Bloomberg) -- Life-sciences company Danaher Corp. has stopped pursuing Catalent Inc. after expressing interest in buying the contract manufacturer, according to people familiar with the matter.
Life-sciences company Danaher Corporation (NYSE: DHR) is reportedly no longer considering a takeover of contract manufacturer Catalent Inc (NYSE: CTLT) after expressing interest in buying the ...
Danaher Corp. will split into two companies on July 2, completing the separation into two two independent, publicly traded ventures that it announced in May 2015. The split will free the two entities ...
Pall Corp. (PLL) stock is rising after the company said it will be acquired by Danaher (DHR) for $13.8 billion. Pall Corp. (PLL) stock is rising after the company said it will be acquired by ...
Catalent is a partner for pharmaceutical and biotechnology companies, helping its customers to bring products to the market in a faster fashion. The company does this by providing oral, injectable ...
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...
Maravai LifeSciences Holdings Inc MRVI reportedly attracted takeover interest from Thomas ... appointed William "Trey" Martin III, a former Danaher executive, as its new CEO.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
